Literature DB >> 25500884

Naturally selected hepatitis C virus polymorphisms confer broad neutralizing antibody resistance.

Justin R Bailey, Lisa N Wasilewski, Anna E Snider, Ramy El-Diwany, William O Osburn, Zhenyong Keck, Steven K H Foung, Stuart C Ray.   

Abstract

For hepatitis C virus (HCV) and other highly variable viruses, broadly neutralizing mAbs are an important guide for vaccine development. The development of resistance to anti-HCV mAbs is poorly understood, in part due to a lack of neutralization testing against diverse, representative panels of HCV variants. Here, we developed a neutralization panel expressing diverse, naturally occurring HCV envelopes (E1E2s) and used this panel to characterize neutralizing breadth and resistance mechanisms of 18 previously described broadly neutralizing anti-HCV human mAbs. The observed mAb resistance could not be attributed to polymorphisms in E1E2 at known mAb-binding residues. Additionally, hierarchical clustering analysis of neutralization resistance patterns revealed relationships between mAbs that were not predicted by prior epitope mapping, identifying 3 distinct neutralization clusters. Using this clustering analysis and envelope sequence data, we identified polymorphisms in E2 that confer resistance to multiple broadly neutralizing mAbs. These polymorphisms, which are not at mAb contact residues, also conferred resistance to neutralization by plasma from HCV-infected subjects. Together, our method of neutralization clustering with sequence analysis reveals that polymorphisms at noncontact residues may be a major immune evasion mechanism for HCV, facilitating viral persistence and presenting a challenge for HCV vaccine development.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25500884      PMCID: PMC4382262          DOI: 10.1172/JCI78794

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  41 in total

Review 1.  The natural history of chronic hepatitis C and what we should do about it.

Authors:  J L Dienstag
Journal:  Gastroenterology       Date:  1997-02       Impact factor: 22.682

2.  Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group.

Authors:  E Kenny-Walsh
Journal:  N Engl J Med       Date:  1999-04-22       Impact factor: 91.245

3.  Production of infectious hepatitis C virus in tissue culture from a cloned viral genome.

Authors:  Takaji Wakita; Thomas Pietschmann; Takanobu Kato; Tomoko Date; Michiko Miyamoto; Zijiang Zhao; Krishna Murthy; Anja Habermann; Hans-Georg Kräusslich; Masashi Mizokami; Ralf Bartenschlager; T Jake Liang
Journal:  Nat Med       Date:  2005-06-12       Impact factor: 53.440

4.  Prospective evaluation of community-acquired acute-phase hepatitis C virus infection.

Authors:  Andrea L Cox; Dale M Netski; Timothy Mosbruger; Susan G Sherman; Steffanie Strathdee; Danielle Ompad; David Vlahov; David Chien; Venkatakrishna Shyamala; Stuart C Ray; David L Thomas
Journal:  Clin Infect Dis       Date:  2005-03-03       Impact factor: 9.079

5.  Neutralizing antibody response during acute and chronic hepatitis C virus infection.

Authors:  C Logvinoff; M E Major; D Oldach; S Heyward; A Talal; P Balfe; S M Feinstone; H Alter; C M Rice; J A McKeating
Journal:  Proc Natl Acad Sci U S A       Date:  2004-06-25       Impact factor: 11.205

6.  Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles.

Authors:  Mayla Hsu; Jie Zhang; Mike Flint; Carine Logvinoff; Cecilia Cheng-Mayer; Charles M Rice; Jane A McKeating
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-21       Impact factor: 11.205

7.  Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization.

Authors:  P Farci; H J Alter; D C Wong; R H Miller; S Govindarajan; R Engle; M Shapiro; R H Purcell
Journal:  Proc Natl Acad Sci U S A       Date:  1994-08-02       Impact factor: 11.205

8.  Neutralizing antibodies against hepatitis C virus and the emergence of neutralization escape mutant viruses.

Authors:  Y K Shimizu; M Hijikata; A Iwamoto; H J Alter; R H Purcell; H Yoshikura
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

9.  Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes.

Authors:  Birke Bartosch; Jean Dubuisson; François-Loïc Cosset
Journal:  J Exp Med       Date:  2003-03-03       Impact factor: 14.307

Review 10.  Genetic diversity and evolution of hepatitis C virus--15 years on.

Authors:  Peter Simmonds
Journal:  J Gen Virol       Date:  2004-11       Impact factor: 3.891

View more
  55 in total

Review 1.  VH1-69 antiviral broadly neutralizing antibodies: genetics, structures, and relevance to rational vaccine design.

Authors:  Fang Chen; Netanel Tzarum; Ian A Wilson; Mansun Law
Journal:  Curr Opin Virol       Date:  2019-03-16       Impact factor: 7.090

2.  HCV Broadly Neutralizing Antibodies Use a CDRH3 Disulfide Motif to Recognize an E2 Glycoprotein Site that Can Be Targeted for Vaccine Design.

Authors:  Andrew I Flyak; Stormy Ruiz; Michelle D Colbert; Tiffany Luong; James E Crowe; Justin R Bailey; Pamela J Bjorkman
Journal:  Cell Host Microbe       Date:  2018-11-14       Impact factor: 21.023

3.  Broadly Neutralizing Antibody Mediated Clearance of Human Hepatitis C Virus Infection.

Authors:  Valerie J Kinchen; Muhammad N Zahid; Andrew I Flyak; Mary G Soliman; Gerald H Learn; Shuyi Wang; Edgar Davidson; Benjamin J Doranz; Stuart C Ray; Andrea L Cox; James E Crowe; Pamela J Bjorkman; George M Shaw; Justin R Bailey
Journal:  Cell Host Microbe       Date:  2018-11-14       Impact factor: 21.023

4.  Limited naturally occurring escape in broadly neutralizing antibody epitopes in hepatitis C glycoprotein E2 and constrained sequence usage in acute infection.

Authors:  Chaturaka Rodrigo; Melanie R Walker; Preston Leung; Auda A Eltahla; Jason Grebely; Gregory J Dore; Tanya Applegate; Kimberly Page; Sunita Dwivedi; Julie Bruneau; Meghan D Morris; Andrea L Cox; William Osburn; Arthur Y Kim; Janke Schinkel; Naglaa H Shoukry; Georg M Lauer; Lisa Maher; Margaret Hellard; Maria Prins; Fabio Luciani; Andrew R Lloyd; Rowena A Bull
Journal:  Infect Genet Evol       Date:  2017-01-05       Impact factor: 3.342

5.  Affinity maturation of a broadly neutralizing human monoclonal antibody that prevents acute hepatitis C virus infection in mice.

Authors:  Zhen-Yong Keck; Yong Wang; Patrick Lau; Garry Lund; Sneha Rangarajan; Catherine Fauvelle; Grant C Liao; Frederick W Holtsberg; Kelly L Warfield; M Javad Aman; Brian G Pierce; Thomas R Fuerst; Justin R Bailey; Thomas F Baumert; Roy A Mariuzza; Norman M Kneteman; Steven K H Foung
Journal:  Hepatology       Date:  2016-10-28       Impact factor: 17.425

6.  Global mapping of antibody recognition of the hepatitis C virus E2 glycoprotein: Implications for vaccine design.

Authors:  Brian G Pierce; Zhen-Yong Keck; Patrick Lau; Catherine Fauvelle; Ragul Gowthaman; Thomas F Baumert; Thomas R Fuerst; Roy A Mariuzza; Steven K H Foung
Journal:  Proc Natl Acad Sci U S A       Date:  2016-10-26       Impact factor: 11.205

7.  Synergistic anti-HCV broadly neutralizing human monoclonal antibodies with independent mechanisms.

Authors:  Madeleine C Mankowski; Valerie J Kinchen; Lisa N Wasilewski; Andrew I Flyak; Stuart C Ray; James E Crowe; Justin R Bailey
Journal:  Proc Natl Acad Sci U S A       Date:  2017-12-18       Impact factor: 11.205

8.  Hepatitis C virus resistance to broadly neutralizing antibodies measured using replication-competent virus and pseudoparticles.

Authors:  Lisa N Wasilewski; Stuart C Ray; Justin R Bailey
Journal:  J Gen Virol       Date:  2016-09-21       Impact factor: 3.891

9.  Hepatitis C Virus Escape Studies of Human Antibody AR3A Reveal a High Barrier to Resistance and Novel Insights on Viral Antibody Evasion Mechanisms.

Authors:  Rodrigo Velázquez-Moctezuma; Andrea Galli; Mansun Law; Jens Bukh; Jannick Prentoe
Journal:  J Virol       Date:  2019-02-05       Impact factor: 5.103

Review 10.  Viral evasion and challenges of hepatitis C virus vaccine development.

Authors:  Brian G Pierce; Zhen-Yong Keck; Steven Kh Foung
Journal:  Curr Opin Virol       Date:  2016-09-19       Impact factor: 7.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.